Abeona Therapeutics Inc. (ABEO) Reaches $20.00 After 8.00% Up Move; Flippin Bruce & Porter Trimmed Target (TGT) Holding

April 18, 2018 - By Henry Gaston

Target Corporation (NYSE:TGT) Logo

The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) is a huge mover today! The stock increased 3.63% or $0.7 during the last trading session, reaching $20. About 459,789 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since April 18, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.The move comes after 7 months positive chart setup for the $944.54M company. It was reported on Apr, 18 by Barchart.com. We have $21.60 PT which if reached, will make NASDAQ:ABEO worth $75.56M more.

Flippin Bruce & Porter Inc decreased Target Corp (TGT) stake by 4.14% reported in 2017Q4 SEC filing. Flippin Bruce & Porter Inc sold 6,748 shares as Target Corp (TGT)’s stock rose 4.77%. The Flippin Bruce & Porter Inc holds 156,193 shares with $10.19M value, down from 162,941 last quarter. Target Corp now has $39.15B valuation. The stock increased 0.30% or $0.22 during the last trading session, reaching $72.67. About 780,371 shares traded. Target Corporation (NYSE:TGT) has risen 28.46% since April 18, 2017 and is uptrending. It has outperformed by 16.91% the S&P500.

Analysts await Abeona Therapeutics Inc. (NASDAQ:ABEO) to report earnings on May, 21. They expect $-0.19 EPS, down 46.15% or $0.06 from last year’s $-0.13 per share. After $-0.19 actual EPS reported by Abeona Therapeutics Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $944.54 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 39 analyst reports since December 16, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Wednesday, February 7. Cantor Fitzgerald has “Buy” rating and $34.0 target. H.C. Wainwright maintained the shares of ABEO in report on Monday, September 18 with “Buy” rating. The firm has “Buy” rating given on Thursday, September 14 by RBC Capital Markets. The firm has “Buy” rating by Citigroup given on Tuesday, October 10. The firm earned “Buy” rating on Tuesday, March 20 by Cantor Fitzgerald. On Friday, October 6 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was maintained on Thursday, February 8 by H.C. Wainwright. On Thursday, August 24 the stock rating was maintained by H.C. Wainwright with “Buy”. On Thursday, September 29 the stock rating was maintained by Maxim Group with “Buy”. The company was maintained on Tuesday, July 18 by Maxim Group.

Analysts await Target Corporation (NYSE:TGT) to report earnings on May, 16. They expect $1.38 earnings per share, up 14.05% or $0.17 from last year’s $1.21 per share. TGT’s profit will be $743.53M for 13.16 P/E if the $1.38 EPS becomes a reality. After $1.37 actual earnings per share reported by Target Corporation for the previous quarter, Wall Street now forecasts 0.73% EPS growth.

Among 29 analysts covering Target Corporation (NYSE:TGT), 11 have Buy rating, 3 Sell and 15 Hold. Therefore 38% are positive. Target Corporation had 89 analyst reports since July 21, 2015 according to SRatingsIntel. M Partners maintained the shares of TGT in report on Thursday, February 25 with “Neutral” rating. As per Friday, August 18, the company rating was maintained by BMO Capital Markets. Bank of America maintained the stock with “Buy” rating in Friday, August 18 report. On Friday, February 10 the stock rating was initiated by Susquehanna with “Neutral”. Stifel Nicolaus maintained Target Corporation (NYSE:TGT) rating on Wednesday, August 9. Stifel Nicolaus has “Hold” rating and $5800 target. Jefferies maintained the stock with “Hold” rating in Tuesday, October 3 report. The firm has “Hold” rating by Barclays Capital given on Friday, January 5. The rating was maintained by Cowen & Co with “Hold” on Thursday, September 28. The rating was maintained by UBS with “Neutral” on Thursday, November 19. The stock has “Underperform” rating by Wolfe Research on Wednesday, March 1.

Target Corporation (NYSE:TGT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: